Browse the evidence

GLP-1 receptor agonists (GLP-1RAs) have adverse events associated with their increased use.

Practitioners should be aware of the potential adverse events when prescribing GLP-1RAs.

Weight loss magnitude was lower in patients taking GLP-1 RAs compared to postbariatric patients (29.9 kg vs 47.2 kg).

Understanding the differences in weight loss can help tailor interventions for patients seeking body contouring.

GLP-1RAs users demonstrated significantly reduced risks of poor functional outcomes (odds ratio 0.37, 95% CI 0.21-0.66).

Using GLP-1 receptor agonists may enhance functional recovery in patients post-treatment.

GLP-1RAs users had significantly reduced risks of new subarachnoid hemorrhage (odds ratio 0.39, 95% CI 0.27-0.56).

GLP-1 receptor agonists may lower the risk of subarachnoid hemorrhage in treated patients.

GLP-1 agonists may decrease sexual desire through increased serotonergic activity at the 5-HT2C receptor.

Clinicians should consider the potential impact of GLP-1 agonists on sexual desire when prescribing these medications.

The effects of GLP-1 agonists on sexual desire may be overlooked due to competing influences.

Awareness of these competing influences is crucial for healthcare providers managing patients on GLP-1 agonists.

Systematic measurement of sexual desire should be prioritized in future research on GLP-1 agonists.

Researchers should include sexual desire as a key outcome in studies involving GLP-1 agonists.

Gastrointestinal complaints were common but did not significantly influence satisfaction ratings or decisions to continue treatment.

Practitioners should note that while gastrointestinal side effects are common, they may not deter patients from continuing treatment if weight loss is achieved.

Both agents require clinicians to reconceptualize obesity as a chronic disease needing ongoing pharmacological management.

Practitioners should adopt a long-term management strategy for obesity treatment.

A modified prolactin-releasing peptide, NN501, reduces body weight primarily through sustained fatty acid oxidation rather than hypophagia.

NN501 may be a viable alternative therapy for obesity management focusing on fatty acid oxidation.

NN501 causes weight loss without causing obvious aversive responses.

NN501 may provide a weight loss option without the side effects commonly associated with other treatments.

GLP-1 receptor agonists (GLP-1RAs) do not increase the risk of corticosteroid use in patients with inflammatory bowel disease (IBD) compared to non-GLP-1 users.

Clinicians can consider GLP-1RAs for weight management in IBD patients without concern for increased corticosteroid use.

Up to 33% of the weight lost on GLP-1 RAs may be lean tissue mass.

Practitioners should monitor body composition changes in patients using GLP-1 RAs.

Discontinuation rates for GLP-1 RAs can be up to 80% after 2 years.

Practitioners should be aware of high discontinuation rates when prescribing GLP-1 RAs.

GLP-1RAs may raise safety concerns related to weight loss and altered glucose regulation in ALS.

Monitoring for weight loss and glucose regulation is essential when considering GLP-1RAs for ALS.

LLM responses provided appropriate information about standard GLP1RA-related queries but lacked updated information on emerging concerns.

Practitioners should be aware that while LLMs can provide useful information, they may not reflect the latest developments in GLP1RA therapy.

Internet search responses were more heterogeneous and often commercially biased.

Practitioners should critically evaluate internet sources for GLP1RA information due to potential bias.

Reoperation odds among ACDF/GLP-1RA patients were significantly reduced at 12 months (4% vs. 6%; OR=0.689) and 24 months postoperatively (5% vs. 7%; OR=0.692).

GLP-1RAs may help reduce the need for reoperation in ACDF patients.

GLP-1RA use was associated with significantly reduced odds of pseudarthrosis by more than 20% and reoperation by more than 30% at 24 months following ACDF.

GLP-1RAs may significantly improve postoperative outcomes in ACDF patients.

GLP-1 receptor agonists (GLP-1RAs) reduce the risk of major adverse cardiovascular events and non-fatal stroke in patients with type 2 diabetes mellitus.

Practitioners should consider GLP-1RAs as a therapeutic option for reducing cardiovascular risks in patients with type 2 diabetes.

GLP-1RAs provide direct neurovascular protection by stabilizing the blood-brain barrier and modulating neuroinflammation.

GLP-1RAs may be beneficial in protecting brain health and reducing stroke risk.

Meta-regression showed no significant effect modification by age, body mass index, HbA1c, follow-up duration, or sodium-glucose co-transporter 2 inhibitors use.

The effectiveness of semaglutide is consistent regardless of these common patient characteristics.

Several classes of medications have been explored to target different pathways and receptors to preserve lean body mass during weight loss.

Practitioners may consider pharmacological options to help preserve muscle mass during weight loss.

Excess visceral abdominal fat (EVAF) can occur in people living with HIV-1 even with normal or mildly elevated body mass index (BMI).

Healthcare providers should assess visceral fat in PLWH regardless of BMI.